Press coverage about Enzymotec (NASDAQ:ENZY) has trended positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Enzymotec earned a coverage optimism score of 0.36 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.1639541610912 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Enzymotec traded down $0.02, hitting $11.85, during trading hours on Friday, according to MarketBeat.com. The company had a trading volume of 98,500 shares, compared to its average volume of 120,557. Enzymotec has a 52-week low of $6.30 and a 52-week high of $12.35.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.